Michael Kelly

Michael Kelly

Director/Board Member at ARS PHARMACEUTICALS, INC.

Net worth: 499 350 $ as of 31/08/2026

61 year
Health Technology
Consumer Services

Profile

Mr. Michael Kelly is an Independent Director at ARS Pharmaceuticals, Inc. He is on the Board of Directors at ARS Pharmaceuticals Operations, Inc. and ARS Pharmaceuticals, Inc. Mr. Kelly was previously employed as a President, Chief Executive Officer & Director by NervGen Pharma Corp., a President-US Operations by Adapt Pharma, Inc., a President by Covis Pharmaceuticals, Inc., a Senior Vice President-Sales & Marketing by Jazz Pharmaceuticals Plc, a Senior Vice President & General Manager by Azur Pharma, Inc., a Vice President-Commercial Operations by Guilford Pharmaceuticals, Inc., a Member by Azur Pharma Ltd., and a Vice President-Sales and Marketing by Viropharma, Inc. He received his undergraduate degree from The College of New Jersey and an MBA from Rider University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
24/06/2026 83,225 ( 0.08% ) 499 350 $ 31/08/2026

Michael Kelly active positions

CompaniesPositionStart
ARS PHARMACEUTICALS, INC. Director/Board Member 01/05/2019
Director/Board Member 01/05/2019

Former positions of Michael Kelly

CompaniesPositionEnd
NERVGEN PHARMA CORP. Chief Executive Officer 17/07/2025
Chief Operating Officer 01/06/2019
Chief Executive Officer 01/03/2016
Corporate Officer/Principal 27/01/2012
Corporate Officer/Principal 01/01/2012
See the detail of Michael Kelly's experience

Training of Michael Kelly

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

60

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Viropharma, Inc.

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!